Daily Recap - WEDNESDAY
Join panelists Drs. Janet Pope, Richard Conway, Meral El Ramahi and Jack Cush recap the best presentations presented on day four of the 2023 ACR Convergence meeting in San Diego, CA.
Watch video →What's hot
View all perspectives
What's Hot
EXXELERATE Study: Do High RF Titers Impact Response to TNF Inhibitors?
Dr. Jonathan Kay discusses abstract 2148 with Dr. Josef Smolen at the 2023 ACR Convergence meeting in San Diego, CA.
Watch video →
Bimekizumab in Active AS: 5 Year Study
Dr. Atul Deodhar reporting on abstract 0519 from the 2023 ACR Convergence meeting in San Diego, CA.
Watch video →
Cannabinoid Receptor in RA Patients
Dr. Arthur Kavanaugh discusses abstract 0025 at the 2023 ACR Convergence meeting in San Diego, CA.
Watch video →
Treatments in SpA
Dr. Rachel Tate and Dr. Catherine Blakewell discuss treatment options patients in spondyloarthritis at the 2023 ACR Convergence meeting in San Diego, CA. Abstracts discussed include 0520, 0530, 0521 and 0529.
Watch video →
PR3+ in Lupus Nephritis
Dr. Jack Cush discusses abstract 2427 presented at the 2023 ACR Convergence meeting in San Diego, CA.
Watch video →
Simulated Trials to Counter ORAL Survelliance
Dr. Jack Cush and Dr. Janet Pope at the 2023 ACR Convergence meeting in San Diego, CA.
Watch video →
Difficult to Treat axSpA
Dr. Peter Nash reports on abstracts 0514 and 0538 from the 2023 ACR Convergence meeting in San Diego, CA.
Watch video →
Window of Opportunity in PsA
Dr. Peter Nash discusses a study that looks at the window of opportunity for treatment of PsA at the 2023 ACR Convergence meeting in San Diego, CA.
Watch video →
TMP SMX Prophylaxis in GPA
Dr. Jack Cush and Dr. Janet Pope discuss abstract 1584 presented at the 2023 ACR Convergence meeting in San Diego, CA.
Watch video →
Richard Conway
2 years 1 month ago
Plasma MMPs and RA-ILD. Strong association MMPs 7 & 9 with prevalent RA-ILD. Abstr#0770 #ACR23 @RheumNow https://t.co/5qWeK3lAly https://t.co/SyZY2OhcbH
Aurelie Najm
2 years 1 month ago
2 yrs extension of DRESS-PS study
100+ pts w/ PsA and AxSPA
-70% LDA state in both Ctrl & Intervention gps
-strong recovery after relapse
No difference efficacy protocolized & routine care tapering but inferior TNFi use (52 vs. 77%) in Intervention gp
@RheumNow #ACR23 ABST0775 https://t.co/V2DqCjT0w3
Dellal
2 years 1 month ago
#ACR23
IV secukinumab vs placebo at 52 Weeks
@RheumNow https://t.co/4zQa37tN4l
Eric Dein
2 years 1 month ago
Abs#0608 #ACR23 @RheumNow
Cenerimod: sphigosine 1-phos (S1P) 1 receptor modulator for SLE
P2 CARE Study
51% of pts had high IFN1 sign., ass w/ high dsDNA
Cenerimod 4 mg: decreased dsDNA and IFN-a protein at 6 mo vs b/l
In high IFN pts, 4 mg Cen: decrease SLEDAI, SRI-4
Eric Dein
2 years 1 month ago
Abs#595 #ACR23 @RheumNow
R Furie on 4 yr TULIP-LTE pts with b/l renal involvement
33% on anifrolumab continued to wk 208 vs PBO 6%
Renal improvement at w208 in 9/10 pts, vs no avail PBO data
Conclusion: more Anifrolumab pts remained in study & reached SLEDAI-2K renal improvement
Richard Conway
2 years 1 month ago
Cowley et al @sharoncowley01 Subclinical GCA in 17.5% with new PMR. Males with higher ESR more likely to have subclinical GCA. Subclinical GCA more axillary artery. Abstr#0747 #ACR23 #ACRbest @RheumNow https://t.co/CghmX1TKpf https://t.co/MJawtslLud
Robert B Chao, MD
2 years 1 month ago
Phase 3 Study of IV Secukinumab for treatment of PsA - efficacious and safety profile similar to Subq version
~60% ACR 50 response maintained at week 52
2nd responses of MDA, PASI90, enthesitis, dactylitis resolution met
@RheumNow #ACR23 Abs#0776 https://t.co/jikWd4fnGm
ReumaJoven
2 years 1 month ago
Entrevista de @RheumNow a las doctoras Griselda Serna Peña y Diana Flores Gutierrez sobre su trabajo de Screening y salud secual en pacientes con enfermedades reumáticas
#ACR23 @SernaDra @ColMexReuma https://t.co/SyuFVXM9Sf
Dr. John Cush RheumNow
2 years 1 month ago
RheumNow’s expanded coverage of the #ACR23 annual meeting is sponsored in part by Bristol Myers Squibb and UCB. All content is chosen by RheumNow and its faculty
TheDaoIndex KDAO2011
2 years 1 month ago
Reporting for @RheumNow! #ACR23 follow our coverage! @ACRheum @uptotate @Yuz6Yusof @ericdeinmd https://t.co/e4ShTzZhrE
Eric Dein
2 years 1 month ago
Upadacitinib on wearable device-measure activity
SELECT-AXIS 2
Abs#0530 #ACR23 @RheumNow
UPA had numerically higher mean daily step counts than PBO
11% improvement v PBO at wk 14 (diff of 345 steps/day)
Sedentary pts: 22% improvement in daily step count from b/l on UPA (4% PBO) https://t.co/Gq91TmvfZC
Poster Hall